Literature DB >> 16473407

Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.

Shigeto Kawai1, Yasuo Koishihara, Shin-ichiro Iida, Shuji Ozaki, Toshio Matsumoto, Masaaki Kosaka, Hisafumi Yamada-Okabe.   

Abstract

A humanized monoclonal antibody (mAb) against HM1.24 (AHM) caused antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma (MM) cells. Here, we constructed a conventional non-radioisotope method that quantifies the amount of HM1.24 using fluorescein-labeled AHM. More than 10(4) molecules/cell of HM1.24 were detected in 12 out of 14 patients' MM cells, and a linear correlation was found between ADCC by AHM and the amounts of HM1.24. Thus, AHM is likely to be more efficacious against MM cells with high levels of HM1.24. This conventional non-RI method to quantify HM1.24 will be useful to select patients most likely to respond to AHM.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16473407     DOI： 10.1016/j.leukres.2005.11.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  8 in total

1.  Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.

Authors:  Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans.

Authors:  Elina Erikson; Tarek Adam; Sarah Schmidt; Judith Lehmann-Koch; Benjamin Over; Christine Goffinet; Christoph Harter; Isabelle Bekeredjian-Ding; Serkan Sertel; Felix Lasitschka; Oliver T Keppler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

3.  Upregulation of BST-2/Tetherin by HIV infection in vivo.

Authors:  Stefanie Homann; Davey Smith; Susan Little; Douglas Richman; John Guatelli
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.

Authors:  Takeshi Harada; Shuji Ozaki; Asuka Oda; Daisuke Tsuji; Akishige Ikegame; Masami Iwasa; Kengo Udaka; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Yoshiaki Kuroda; Shigeto Kawai; Kohji Itoh; Hisafumi Yamada-Okabe; Toshio Matsumoto; Masahiro Abe
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 5.  Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.

Authors:  Takeshi Harada; Shuji Ozaki
Journal:  Biomed Res Int       Date:  2014-07-17       Impact factor: 3.411

6.  Tissue-specific effects of an anti-desmoglein-3 ADCC antibody due to expression of the target antigen and physiological characteristics of the mouse vagina.

Authors:  Etsuko Fujii; Shinichi Funahashi; Kenji Taniguchi; Shigeto Kawai; Kiyotaka Nakano; Atsuhiko Kato; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2019-12-19       Impact factor: 1.628

7.  Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.

Authors:  Shin-Ichi Funahashi; Shigeto Kawai; Etsuko Fujii; Kenji Taniguchi; Kiyotaka Nakano; Shumpei Ishikawa; Hiroyuki Aburatani; Masami Suzuki
Journal:  J Biochem       Date:  2018-12-01       Impact factor: 3.387

8.  IL-27 increases BST-2 expression in human monocytes and T cells independently of type I IFN.

Authors:  Christina Guzzo; Masany Jung; Ashley Graveline; Bruce W Banfield; Katrina Gee
Journal:  Sci Rep       Date:  2012-12-13       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.